Leukotrienes and other Lipoxygenase Products  Edited by P.J. Piper Research studies press, John Wiley and Sons; Chichester and New York, 1983 xiv + 353 pages. £19.50 by Hoult, Robin
Volume 164, number 1 FEBS LETTERS November 1983 
Leukotrienes and other Lipoxygenase Products 
Edited by P. J. Piper 
Research Studies Press, John Wiley and Sons; Chichester and New York, 1983 
xiv + 353 pages. f19.50 
This useful and important book ought certainly to 
find its way onto the shelves of all those involved 
in research on prostaglandins and leukotrienes as 
we1 as into most pharmacology libraries. This is 
because it is a valuable update on leukotriene 
research in the period 1981-82 (much happened in 
that short time) and is a convenient source of much 
of the earlier background work. 
In fact, this is the second volume in the so-called 
‘Prostaglandin Series’ to be devoted to 
leukotrienes, and, like the earlier one, contains the 
proceedings of a conference held at the Royal Col- 
lege of Surgeons, London. The first meeting was 
held in 1980, to coincide with the period when the 
structures of the various slow reacting substances 
(peptidolipid leukotrienes) and their biosynthetic 
sequences had been more or less established. 
During the ensuing two years many more in- 
vestigators became busy in the field - some would 
say jumped on the bandwagon - and have started 
an exhaustive study of the properties and possible 
physiological relevance of these mediators. Indeed, 
the volume of literature on lipoxygenase products 
promises soon to rival that on prostaglandins. 
With 43 contributions, the present book reviews 
the chemistry and synthesis of leukotrienes and 
deals with one of several recently developed 
methods of radioimmunoassay, as well as pro- 
viding a preliminary report of fast atom bombard- 
ment mass spectrometry of leukotrienes. Equally 
applicable to other eicosanoids uch as the classical 
prostaglandins and sensitive at the microgram 
level, this powerful technique obviates the need for 
sample derivatisation. There are also important 
contributions on mast cell heterogeneity, im- 
munocytochemical localisation of LTG and 
stability of leukotrienes, as well as several papers 
on their cardiovascular and pulmonary actions and 
release in various disease models. 
However, progress towards two potential 
matchwinners remains tantalisingly slow. These 
are the development of specific leukotriene an- 
tagonists and specific leukotriene synthesis in- 
hibitors. There are a number of useful leads (some 
of them dealt with here), but perhaps one day soon 
a chance finding will show the way. It goes without 
saying that novel pharmacological agents of this 
sort should have considerable potential for therapy 
of inflammatory and allergic diseases in which the 
leukotrienes are so strongly implicated. 
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